A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Mardepodect (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2008 Actual end date is added as Feb 2008 as reported by ClinicalTrials.gov.
- 11 May 2008 Actual no of patients added as 35 as reported by ClinicalTria;s.gov.